- Home
- UHS vs NBIX Comparison
UHS vs NBIX Comparison
Compare UHS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHS | NBIX |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 14.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | UHS | NBIX |
|---|---|---|
| Price | $225.70 | $155.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $232.58 | $174.84 |
| AVG Volume (30 Days) | 648.8K | ★ 969.8K |
| Earning Date | 10-27-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 39.76 | 12.44 |
| EPS | ★ 21.01 | 4.19 |
| Revenue | ★ $16,992,503,000.00 | $2,682,700,000.00 |
| Revenue This Year | $10.93 | $23.76 |
| Revenue Next Year | $4.96 | $18.01 |
| P/E Ratio | ★ $10.76 | $36.98 |
| Revenue Growth | 10.21 | ★ 19.61 |
| 52 Week Low | $152.33 | $84.23 |
| 52 Week High | $246.33 | $160.18 |
Technical Indicators
Market Signals| Indicator | UHS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 63.85 |
| Support Level | $228.00 | $150.26 |
| Resistance Level | $232.86 | $154.35 |
| Average True Range (ATR) | 5.89 | 4.30 |
| MACD | -1.89 | 1.02 |
| Stochastic Oscillator | 10.07 | 77.63 |
Price Performance
Historical ComparisonAbout UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.